GlassScriptPhysician profile
Stephen Alva Turner
NPI 1508866252
$3,364.98
in general payments reported to CMS, 2019-2025
22 companies · $56.54 in 2025
The $56.54 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $946 · 2020: $330 · 2021: $593 · 2022: $631 · 2023: $463 · 2024: $345 · 2025: $56.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $864.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $722.36 | 2019-2020 | |
| Medtronic, INC. | $490.28 | 2021-2024 | Linq II, Azure Xt Dr Mri Surescan, Tyrx |
| Pfizer INC. | $427.75 | 2019-2024 | |
| Boston Scientific Corporation | $327.07 | 2022-2024 | |
| Preventice Services, LLC | $265.89 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $227.27 | 2019-2022 | |
| Abiomed | $162.52 | 2022-2023 | Impella |
| E.R. Squibb & Sons, L.L.C. | $135.62 | 2019-2024 | Camzyos, Eliquis |
| Philips North America LLC | $89.46 | 2019 | |
| Esperion Therapeutics, INC. | $81.04 | 2021 | |
| Abbott Laboratories | $64.94 | 2021-2024 | Mitraclip |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.50 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $54.80 | 2021-2025 | Lifevest |
| Irhythm Technologies, INC. | $40.83 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $40.73 | 2019-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $35.95 | 2025 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $35.05 | 2020-2023 | |
| Amgen INC. | $33.26 | 2019-2023 | Repatha |
| Merck Sharp & Dohme LLC | $32.43 | 2021-2022 | |
| Acist Medical Systems, INC. | $18.00 | 2021 | |
| Gilead Sciences, INC. | $12.68 | 2019 | |
| Vivaquant INC, Dba Rhythm Express | $6.55 | 2024 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.